SAN DIEGO, September 12, 2017 – Polaris Group announced today that its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) demonstrated a good safety profile and an efficacy signal as monotherapy in a phase 2 trial in relapsed/refractory or poor-risk acute myeloid leukemia (AML) patients, as reported in the journal Scientific…
SAN DIEGO, August 2, 2017 – Polaris Group announced today that the first patient has been dosed in its randomized, placebo-controlled, double blind phase 2/3 trial (ATOMIC-meso) in malignant pleural mesothelioma (MPM) patients. Patients will be randomized to receive ADI-PEG 20 (pegylated arginine deiminase) or placebo in combination with pemetrexed…
SAN DIEGO, July 14, 2017 – Polaris Group announced today that the first patient has been dosed in its phase 1 trial of ADI-PEG 20 in combination with pembrolizumab for the treatment of advanced solid tumors. In addition to a global phase 2/3 trial in malignant plural mesothelioma featuring ADI-PEG…
SAN DIEGO, June 5, 2017 – Polaris Group announced today that its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) in combination with pemetrexed and cisplatin (ADIPemCis) is active in argininosuccinate synthetase (ASS1) deficient malignant pleural mesothelioma (MPM), including non-epithelioid MPM, which carries an unfavorable prognosis and historically responds poorly to…
SAN DIEGO, April 20, 2017 – Polaris Group announced today that its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) in combination with pemetrexed and cisplatin (ADIPemCis) demonstrated a good safety profile and a strong efficacy signal in argininosuccinate synthetase (ASS1) deficient malignant pleural mesothelioma (MPM) and non-small cell lung carcinoma…
SAN DIEGO, January 20, 2017 – Polaris Group announced today that the first patient has been dosed in its phase 1 trial of ADI-PEG 20 in combination with low-dose cytarabine for the treatment of acute myeloid leukemia (AML) in older patients. In addition to a global phase 2/3 study in…
SAN DIEGO, January 19, 2017 – Polaris Group announced today results from an ongoing phase 1b study conducted at Memorial Sloan Kettering Cancer Center that tests combining ADI-PEG 20 with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in patients with advanced hepatocellular carcinoma (HCC) and other gastrointestinal malignancies. The results will be presented at the 2017 Gastrointestinal Cancers Symposium in San Francisco.
SAN DIEGO, Nov. 8, 2016 /PRNewswire/ — Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can selectively enhance the effect of radiation in argininosuccinate synthetase (ASS1) deficient pancreatic tumors according to results presented by researchers from MD Anderson Cancer Center at the annual meeting of the American Society for Radiation Oncology (ASTRO).
SAN DIEGO, Oct. 24, 2016 /PRNewswire/ — Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can boost anti-tumor immune surveillance according to research presented by Polaris at the 2016 American Association for Cancer Research Tumor Immunology and Immunotherapy conference in Boston.
CHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median OS was 7.8 months for ADI-PEG 20 vs. 7.4 months for placebo (p = 0.884, HR=1.022 [95% CI: 0.847, 1.233]).